Related Experiment Videos
Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse
Michel Kalamarides1, Michiko Niwa-Kawakita, Hélène Leblois
1INSERM U434, Fondation Jean Dausset-Centre d'Etude du Polymorphisme Humain, 75010 Paris, France.
Abstract:
Biallelic NF2 gene inactivation is common in sporadic and in neurofibromatosis type 2 (NF2)-related meningiomas. We show that, beginning at four months of age, thirty percent of mice with arachnoidal cell Cre-mediated excision of Nf2 exon 2 developed a range of meningioma subtypes histologically similar to the human tumors. Additional hemizygosity for p53 did not modify meningioma frequency or progression suggesting that Nf2 and p53 mutations do not synergize in meningeal tumorigenesis. This first mouse model initiated with a genetic lesion found in human meningiomas provides a powerful tool for investigating tumor progression and for the preclinical evaluation of therapeutic interventions.
Insights
Researchers created a mouse model for meningiomas by inactivating the NF2 gene. This model mimics human tumors and will aid in studying tumor growth and testing new treatments.
Area of Science:
- Oncology
- Genetics
- Neuroscience
Background:
- Biallelic inactivation of the NF2 gene is frequently observed in both sporadic and neurofibromatosis type 2 (NF2)-related meningiomas.
- The NF2 gene is a known tumor suppressor gene crucial for cell growth regulation.
Purpose of the Study:
- To develop the first mouse model of meningioma initiated by a genetic lesion found in human tumors.
- To investigate the role of NF2 gene inactivation in meningioma development and progression.
- To provide a preclinical tool for evaluating therapeutic interventions for meningiomas.
Main Methods:
- Generation of a mouse model using Cre-mediated excision of exon 2 of the Nf2 gene in arachnoidal cells.
- Histological analysis of tumors developed in the mouse model.
- Evaluation of the impact of additional p53 hemizygosity on meningioma development and progression.
Main Results:
- Approximately thirty percent of mice with Nf2 exon 2 excision developed various meningioma subtypes.
- The developed meningiomas were histologically similar to human meningiomas.
- The absence of p53 did not alter the frequency or progression of meningiomas, indicating no synergistic effect with Nf2 mutations in this context.
Conclusions:
- The developed mouse model represents the first genetic model of meningioma initiated by a relevant human genetic lesion.
- This model serves as a valuable tool for studying meningioma tumor progression.
- The model is suitable for preclinical evaluation of potential therapeutic strategies for meningiomas.